Erratum to: “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice”

During the processing of our article published in the September issue of Haematologica,¹ panels A and B in Figure 4 were unfortunately replaced by those of Figure 3A and 3B. We deeply apologize for this mistake and regret any inconvenience this may have caused. The correct panels A and B for Figure 4 are shown below.

Figure 4.Tail artery transection model. (A) Factor VIII (FVIII)-deficient mice were given intravenously vehicle, various doses of FVIII (2.5, 5, and 10 IU/kg), emicizumab (5 mg/kg) or sequence-identical analog of marstacimab (SIA-marstacimab) (1 mg/kg). Estimated plasma concentrations at time of injury were 5 IU/dL FVIII, 10 IU/dL FVIII, 20 IU/dL FVIII, 55 μg/mL emicizumab or 16 μg/ mL SIA-marstacimab. Wild-type (WT) mice were used as control. If mice were not bleeding at 15 minutes (min), clots were dislodged. Mice were monitored for 30 min. During the 30-min observation time, periods of bleeding and bleeding arrest were noted. Bleeding patterns of 4 mice representative for each group are presented. For FVIII-treated mice, data for mice receiving the two lowest doses are depicted. (B) Blood loss for each individual mouse included in the study.

Footnotes

• Received September 5, 2025
• Accepted September 5, 2025

Correspondence

*TS and GMC contributed equally as first authors.

^#VM and CC contributed equally as senior authors

P.J. Lenting peter.lenting@inserm.fr